ADEL 102
Alternative Names: ADEL-102Latest Information Update: 12 Jan 2023
At a glance
- Originator Aptadel Therapeutics
- Class Antineoplastics; Nucleotide aptamers; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Rhabdomyosarcoma
Most Recent Events
- 01 Dec 2022 Early research in Rhabdomyosarcoma in Spain (unspecified route) (Aptadel Therapeutics pipeline, December 2022)